These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 36051879)
1. Allosteric regulation of autoinhibition and activation of c-Abl. Liu Y; Zhang M; Tsai CJ; Jang H; Nussinov R Comput Struct Biotechnol J; 2022; 20():4257-4270. PubMed ID: 36051879 [TBL] [Abstract][Full Text] [Related]
2. Two-state dynamics of the SH3-SH2 tandem of Abl kinase and the allosteric role of the N-cap. Corbi-Verge C; Marinelli F; Zafra-Ruano A; Ruiz-Sanz J; Luque I; Faraldo-Gómez JD Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3372-80. PubMed ID: 23959873 [TBL] [Abstract][Full Text] [Related]
3. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors. Singh VK; Chang HH; Kuo CC; Shiao HY; Hsieh HP; Coumar MS J Biomol Struct Dyn; 2017 Jun; 35(8):1833-1848. PubMed ID: 27353341 [TBL] [Abstract][Full Text] [Related]
4. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251 [TBL] [Abstract][Full Text] [Related]
5. Insight into the allosteric inhibition of Abl kinase. Fallacara AL; Tintori C; Radi M; Schenone S; Botta M J Chem Inf Model; 2014 May; 54(5):1325-38. PubMed ID: 24787133 [TBL] [Abstract][Full Text] [Related]
6. Autoinhibition of Bcr-Abl through its SH3 domain. Smith KM; Yacobi R; Van Etten RA Mol Cell; 2003 Jul; 12(1):27-37. PubMed ID: 12887890 [TBL] [Abstract][Full Text] [Related]
7. Computational dissection of allosteric inhibition of the SH2 domain of Bcr-Abl kinase by the monobody inhibitor AS25. Ji M; Zheng G; Li X; Zhang Z; Jv G; Wang X; Wang J J Mol Model; 2017 Jun; 23(6):183. PubMed ID: 28488190 [TBL] [Abstract][Full Text] [Related]
8. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Skora L; Mestan J; Fabbro D; Jahnke W; Grzesiek S Proc Natl Acad Sci U S A; 2013 Nov; 110(47):E4437-45. PubMed ID: 24191057 [TBL] [Abstract][Full Text] [Related]
9. Enhancement of ABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms. Cao X; Tanis KQ; Koleske AJ; Colicelli J J Biol Chem; 2008 Nov; 283(46):31401-7. PubMed ID: 18796434 [TBL] [Abstract][Full Text] [Related]
10. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance. El Rashedy AA; Olotu FA; Soliman MES Chem Biodivers; 2018 Mar; 15(3):e1700533. PubMed ID: 29325229 [TBL] [Abstract][Full Text] [Related]
11. Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. Dixit A; Verkhivker GM PLoS Comput Biol; 2009 Aug; 5(8):e1000487. PubMed ID: 19714203 [TBL] [Abstract][Full Text] [Related]
12. Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase. Johnson TK; Bochar DA; Vandecan NM; Furtado J; Agius MP; Phadke S; Soellner MB Angew Chem Int Ed Engl; 2021 Sep; 60(37):20196-20199. PubMed ID: 34292655 [TBL] [Abstract][Full Text] [Related]
13. Atomistic Modeling of the ABL Kinase Regulation by Allosteric Modulators Using Structural Perturbation Analysis and Community-Based Network Reconstruction of Allosteric Communications. Astl L; Verkhivker GM J Chem Theory Comput; 2019 May; 15(5):3362-3380. PubMed ID: 31017783 [TBL] [Abstract][Full Text] [Related]
15. c-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in Solution. Badger J; Grover P; Shi H; Panjarian SB; Engen JR; Smithgall TE; Makowski L Biochemistry; 2016 Jun; 55(23):3251-60. PubMed ID: 27166638 [TBL] [Abstract][Full Text] [Related]
16. The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility. Lamontanara AJ; Georgeon S; Tria G; Svergun DI; Hantschel O Nat Commun; 2014 Nov; 5():5470. PubMed ID: 25399951 [TBL] [Abstract][Full Text] [Related]
17. Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface. Wojcik J; Lamontanara AJ; Grabe G; Koide A; Akin L; Gerig B; Hantschel O; Koide S J Biol Chem; 2016 Apr; 291(16):8836-47. PubMed ID: 26912659 [TBL] [Abstract][Full Text] [Related]
18. Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function. Grover P; Shi H; Baumgartner M; Camacho CJ; Smithgall TE PLoS One; 2015; 10(7):e0133590. PubMed ID: 26222440 [TBL] [Abstract][Full Text] [Related]
19. Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors. Panjarian S; Iacob RE; Chen S; Wales TE; Engen JR; Smithgall TE J Biol Chem; 2013 Mar; 288(9):6116-29. PubMed ID: 23303187 [TBL] [Abstract][Full Text] [Related]
20. Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to. Carofiglio F; Trisciuzzi D; Gambacorta N; Leonetti F; Stefanachi A; Nicolotti O Molecules; 2020 Sep; 25(18):. PubMed ID: 32937901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]